Erteberel

Drug Profile

Erteberel

Alternative Names: LY 500307; SERBA-1

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Indiana University
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Dec 2015 Phase-II development for Schizophrenia is ongoing in USA (NCT01874756)
  • 08 Jul 2011 Erteberel is still in phase II trials for Benign prostatic hyperplasia in USA, Australia, Canada, France, Germany, Greece, Italy and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top